Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pharmacyclics, Inc.    

PHARMACYCLICS, INC.
Mes dernières consult.
Most popular
  Report  
SummaryNewsCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pharmacyclics Inks Agreement With Novo Nordisk for Molecule Inhibitor

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/10/2012 | 12:25am CEST
   By Kristin Jones 
 

Pharmacyclics Inc. (>> Pharmacyclics, Inc.) has inked an agreement with Novo Nordisk A/S (NVO, NOVO-B.KO) giving the Danish insulin producer rights to certain uses of its Factor VIIa molecule inhibitor, according to a regulatory filing.

Pharmacyclics shares rose 3.75% to $67.20 in after-hours trading. Through the close, the stock had more than doubled in the past six months.

Under the terms of the agreement, Novo Nordisk will acquire the world-wide rights to PCI-27483 for specific noncancer-related uses. The Danish company plans to use it as an excipient in an unnamed product within its biopharmaceutical unit.

An excipient is generally an inactive ingredient used to carry or to add a certain consistency to a drug.

Pharmacyclics has been developing PCI-27483 to inhibit the intracellular signaling involved in tumor growth and to thwart the blood clots that afflict some cancer patients.

The biopharmaceutical company expects to receive an upfront payment of $5 million, as well as up to $55 million based on the achievement of certain development, regulatory and sales milestones. It also will receive royalties on sales of Novo Nordisk products that use PCI-27483.

Novo Nordisk's American depositary shares closed Tuesday at $161.38 and were unchanged after hours. The ADS are up 40% so far this year.

Write to Kristin Jones at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pharmacyclics, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 0.35% 285.2 Delayed Quote.-15.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PHARMACYCLICS, INC.
2016PHARMACYCLICS : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceuti..
PU
2016PHARMACYCLICS : AbbVie’s Commitment to Oncology Demonstrated at the 57th A..
PU
2016PHARMACYCLICS : AbbVie Announces Submission of a Supplemental New Drug Applicati..
PU
2016PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients..
PU
2016PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naï..
PU
2016PHARMACYCLICS : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s..
PU
2016PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naï..
PU
2015Alexion to bolster rare disease offering with $8.4 billion deal
RE
2015AbbVie Wraps Up Large Debt Sale for Pharmacyclics Deal
DJ
2015AbbVie Wraps Up Large Debt Sale For Pharmacyclics Deal
DJ
More news
News from SeekingAlpha
2017BIOTECH FORUM DAILY DIGEST : Sector Fails To Breach Upward Resistance Levels Aga.. 
2016Who's Next After Medivation? 
2016Pfizer Pays Up 
2016Smart-Money Healthcare Investing Focuses On Major Biotech Stocks 
2015Investing In Johnson & Johnson's Pharmaceutical Collaborations Can Provide Dr.. 
Chart PHARMACYCLICS, INC.
Duration : Period :
Pharmacyclics, Inc. Technical Analysis Chart | US7169331060 | 4-Traders
Managers
NameTitle
Wulff-Erik von Borcke President
Heow Tan Chief Quality & Technical Operations Officer
Betty Chang Vice President-Research & Biology
Matthew Outten Vice President-Marketing & Marketing Access
Dana Lee Vice President-Clinical Drug Safety
Sector and Competitors
1st jan.Capitalization (M$)
PHARMACYCLICS, INC.0
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873